Titre

Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Rackayová, V.
Auteure/Auteur
Flatt, E.
Auteure/Auteur
Braissant, O.
Auteure/Auteur
Grosse, J.
Auteure/Auteur
Capobianco, D.
Auteure/Auteur
Mastromarino, P.
Auteure/Auteur
McMillin, M.
Auteure/Auteur
DeMorrow, S.
Auteure/Auteur
McLin, V.A.
Auteure/Auteur
Cudalbu, C.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2045-2322
Statut éditorial
Publié
Date de publication
2021-01-26
Volume
11
Numéro
1
Première page
2269
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Chronic liver disease leads to neuropsychiatric complications called hepatic encephalopathy (HE). Current treatments have some limitations in their efficacy and tolerability, emphasizing the need for alternative therapies. Modulation of gut bacterial flora using probiotics is emerging as a therapeutic alternative. However, knowledge about how probiotics influence brain metabolite changes during HE is missing. In the present study, we combined the advantages of ultra-high field in vivo <sup>1</sup> H MRS with behavioural tests to analyse whether a long-term treatment with a multistrain probiotic mixture (VIVOMIXX) in a rat model of type C HE had a positive effect on behaviour and neurometabolic changes. We showed that the prophylactic administration of this probiotic formulation led to an increase in gut Bifidobacteria and attenuated changes in locomotor activity and neurometabolic profile in a rat model of type C HE. Both the performance in behavioural tests and the neurometabolic profile of BDL + probiotic rats were improved compared to the BDL group at week 8 post-BDL. They displayed a significantly lesser increase in brain Gln, a milder decrease in brain mIns and a smaller decrease in neurotransmitter Glu than untreated animals. The clinical implications of these findings are potentially far-reaching given that probiotics are generally safe and well-tolerated by patients.
PID Serval
serval:BIB_9A9CF9B0223E
DOI
PMID
WOS
Permalien
Open Access
Oui
Date de création
2021-02-02T13:34:34.797Z
Date de création dans IRIS
2025-05-21T01:51:35Z
Fichier(s)
En cours de chargement...
Vignette d'image
Nom

2021-SciRep Rackayova.pdf

Version du manuscrit

published

Licence

https://creativecommons.org/licenses/by/4.0

Taille

1.97 MB

Format

Adobe PDF

PID Serval

serval:BIB_9A9CF9B0223E.P001

URN

urn:nbn:ch:serval-BIB_9A9CF9B0223E1

Somme de contrôle

(MD5):99863598eb8638ad5ddedb0e9130d362